Qiagen (QGEN) Investor presentation summary

Strategic direction and growth targets

• Aims for solid, profitable growth with a focus on expanding core pillars and operational efficiency.

• Targets at least $2 billion in net sales from growth pillars by 2028, with a 7% CAGR (2024–28).

• Seeks to expand adjusted operating income margin by at least 250 basis points to ≥31% by 2028.

• Plans to return at least $1 billion to shareholders from 2024–28, excluding M&A.

Product portfolio and innovation

• Maintains a balanced portfolio across sample technologies, diagnostic solutions, PCR/NGS, and digital insights.

• Acquired Parse Biosciences to enter the high-growth single-cell market, enhancing sample tech leadership.

• Launched new automation platforms (QIAsymphony Connect, QIAsprint Connect, QIAmini) to address all lab sizes.

• Expanded QIAstat-Dx menu and submitted new blood culture panels for regulatory approval.

• Advanced QuantiFERON automation with next-gen products, increasing throughput and efficiency.

Financial performance (Q4 and FY 2025)

• FY 2025 net sales reached $2.09 billion (+5% CER), with Q4 growth ahead of outlook.

• Adjusted diluted EPS for FY 2025 was $2.38 ($2.40 CER), exceeding guidance.

• Adjusted operating income margin improved to 29.5% for FY 2025, up 0.8 ppt despite tariff and currency headwinds.

• Operating cash flow for FY 2025 was $654 million, absorbing higher CAPEX for IT upgrades.